Reinhart Partners LLC. Sells 16,720 Shares of Encompass Health Co. (NYSE:EHC)

Reinhart Partners LLC. lowered its holdings in Encompass Health Co. (NYSE:EHC) by 2.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 656,320 shares of the company’s stock after selling 16,720 shares during the period. Encompass Health accounts for 2.3% of Reinhart Partners LLC.’s portfolio, making the stock its 18th largest holding. Reinhart Partners LLC.’s holdings in Encompass Health were worth $60,611,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. UMB Bank n.a. grew its stake in Encompass Health by 387.7% during the third quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after buying an additional 252 shares during the last quarter. V Square Quantitative Management LLC grew its stake in Encompass Health by 53.0% during the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock worth $39,000 after buying an additional 140 shares during the last quarter. Avior Wealth Management LLC acquired a new position in shares of Encompass Health during the third quarter worth approximately $40,000. Benjamin F. Edwards & Company Inc. lifted its holdings in Encompass Health by 58.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock valued at $46,000 after buying an additional 198 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Encompass Health in the second quarter worth $58,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Price Performance

NYSE EHC traded up $0.57 on Monday, reaching $91.62. 117,168 shares of the company’s stock traded hands, compared to its average volume of 570,823. The stock has a market cap of $9.23 billion, a PE ratio of 22.13, a P/E/G ratio of 1.30 and a beta of 0.89. The stock has a 50-day simple moving average of $98.23 and a 200 day simple moving average of $93.78. Encompass Health Co. has a 12 month low of $67.94 and a 12 month high of $104.55. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.09. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. Encompass Health’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.86 EPS. As a group, research analysts predict that Encompass Health Co. will post 4.29 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a dividend of $0.17 per share. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.74%. Encompass Health’s dividend payout ratio (DPR) is presently 16.43%.

Wall Street Analysts Forecast Growth

EHC has been the subject of several research reports. Truist Financial reissued a “buy” rating and set a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. UBS Group raised their target price on shares of Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Royal Bank of Canada raised their target price on shares of Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. KeyCorp raised their target price on shares of Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 29th. Finally, Barclays lifted their price objective on shares of Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 29th. Nine investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and an average target price of $107.11.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.